Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (DE:19X)
FRANKFURT:19X
Holding DE:19X?
Track your performance easily
See the Price Targets and Ratings of:
19X Analyst Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
19X Stock 12 Month Forecast
Average Price Target
€128.47
▲(46.36% Upside)
| Highest Price Target€173.68 | Average Price Target€128.47 | Lowest Price Target€106.14 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
Reiterated
12/20/24
Morgan Stanley
Reiterated
12/13/24
Truist Financial
Assigned
11/27/24
Ladenburg Thalmann & Co.
Reiterated
11/27/24
H.C. Wainwright
Reiterated
11/27/24
RBC Capital
Reiterated
11/25/24
Cantor Fitzgerald
Reiterated
11/13/24
Needham
Reiterated
11/13/24
Robert W. Baird
Assigned
11/12/24
Leerink Partners
Reiterated
11/12/24
Guggenheim
€120.61→€130.26
Buy
48.39%
Upside
Reiterated
11/12/24
Axsome Therapeutics (AXSM) PT Raised to $135 at GuggenheimGuggenheim analyst Yatin Suneja raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $135.00 (from $125.00) while maintaining a Buy rating.
Bank of America Securities
€113.85
Buy
29.70%
Upside
Reiterated
11/12/24
Positive Outlook on Axsome Therapeutics Driven by Strong Q3 Results and Pipeline Advancements
Wells Fargo
€135.08
Buy
53.89%
Upside
Reiterated
11/12/24
Promising Growth Potential for Axsome Therapeutics Driven by AXS-05 and Auvelity Success
TD Cowen
€115.78→€120.61
Buy
37.40%
Upside
Reiterated
11/12/24
Axsome Therapeutics: Strong Performance, Promising Pipeline, and Buy Rating Affirmed by Joseph Thome
UBS
€103.24→€101.31
Buy
15.41%
Upside
Reiterated
08/06/24
Axsome Therapeutics (AXSM) PT Lowered to $105 at UBSUBS analyst Ashwani Verma lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $105.00 (from $107.00) while maintaining a Buy rating.
Best Analysts Covering Axsome Therapeutics
Which Analyst Should I Follow If I Want to Buy DE:19X and Sell After:
1 Month
xxx
Success Rate
9/14 ratings generated profit
Average Return
-0.91%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of -0.91% per trade.
3 Months
xxx
Success Rate
14/21 ratings generated profit
Average Return
+48.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +48.87% per trade.
1 Year
2 Years
xxx
Success Rate
24/27 ratings generated profit
Average Return
+24.73%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +24.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
19X Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
12
8
9
9
7
Buy
19
24
28
39
35
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
32
37
48
42
Each month's total comprises the sum of three months' worth of ratings.
19X Financial Forecast
19X Stock Forecast FAQ
What is DE:19X’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is €128.47.
What is DE:19X’s upside potential, based on the analysts’ average price target?
Axsome Therapeutics Inc has 46.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Axsome Therapeutics Inc a Buy, Sell or Hold?
Axsome Therapeutics Inc has a consensus rating of Strong Buy, which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Axsome Therapeutics Inc’s share price target?
The average share price target for Axsome Therapeutics Inc is €128.47. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €173.68 ,and the lowest forecast is €106.14. The average share price target represents 46.36% Increase from the current price of €87.78.
The highest analyst share price target is €173.68 ,and the lowest forecast is €106.14. The average share price target represents 46.36% Increase from the current price of €87.78.
What do analysts say about Axsome Therapeutics Inc?
Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of Axsome Therapeutics Inc?
To buy shares of DE:19X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.